Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,492 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin-R with the US-licensed Humulin® R formulation in healthy subjects: Results from the RHINE-1 (Recombinant Human INsulin Equivalence-1) study.
Plum-Mörschel L, Singh G, Murugesan SMN, Marwah A, Panda J, Loganathan S, Athalye SN. Plum-Mörschel L, et al. Among authors: singh g. Diabetes Obes Metab. 2022 Apr;24(4):713-721. doi: 10.1111/dom.14635. Epub 2022 Jan 28. Diabetes Obes Metab. 2022. PMID: 34981621 Free PMC article. Clinical Trial.
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US-licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE-3 (Recombinant Human INsulin Equivalence-3) study.
Plum-Mörschel L, Klein O, Singh G, Murugesan SMN, Marwah A, Sharma N, Panda J, Loganathan S, Lakshmi GC, Athalye SN. Plum-Mörschel L, et al. Among authors: singh g. Diabetes Obes Metab. 2022 Sep;24(9):1819-1828. doi: 10.1111/dom.14768. Epub 2022 Jun 6. Diabetes Obes Metab. 2022. PMID: 35589611 Free PMC article. Clinical Trial.
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US-licensed Humulin® N formulation in healthy subjects: Results from the RHINE-2 (Recombinant Human INsulin Equivalence-2) study.
Andersen G, Singh G, Murugesan SMN, Gogineni R, Sharma N, Panda J, Marwah A, Loganathan S, Athalye SN. Andersen G, et al. Among authors: singh g. Diabetes Obes Metab. 2023 Jun;25(6):1485-1494. doi: 10.1111/dom.14994. Epub 2023 Feb 14. Diabetes Obes Metab. 2023. PMID: 36708333 Clinical Trial.
Promotion of Cardiovascular Health in Africa: The Alliance for Medical Research in Africa (AMedRA) Expert Panel.
Ka MM, Gaye ND, Ahadzi D, Baker-Smith CM, Ndao SCT, Wambugu V, Singh G, Gueye K, Seck D, Dia K, Allen NB, Ba A, Mboup WN, Yassine R, Guissé PM, Anne M, Aw F, Bèye SM, Diouf MT, Diaw M, Belkhadir J, Wone I, Kohen JE, Mbaye MN, Ngaide AA, Liyong EA, Sougou NM, Lalika M, Ale BM, Jaiteh L, Mekonnen D, Bukachi F, Lorenz T, Ntabadde K, Mampuya W, Houinato D, Kitara DL, Kane A, Seck SM, Fall IS, Tshilolo L, Samb A, Owolabi M, Diouf M, Lamptey R, Kengne AP, Maffia P, Clifford GD, Sattler ELP, Mboup MC, Jobe M, Gaye B. Ka MM, et al. Among authors: singh g. JACC Adv. 2024 Nov 20;3(12):101376. doi: 10.1016/j.jacadv.2024.101376. eCollection 2024 Dec. JACC Adv. 2024. PMID: 39817059 Free PMC article. Review.
Docetaxel and Niclosamide-loaded Nanofiber systems for Improved Chemo-therapeutic Activity and Resistance Reversal in Prostate Cancer.
Shah S, Famta P, Vambhurkar G, Kumar R, Pandey G, Singh G, Wagh S, Kanaujiya S, Arya DK, Sharma A, Shinde A, Bhanu Prasad S, Chandankar S, Shinde S, Sharma A, Rajinikanth PS, Khatri DK, Asthana A, Srivastava S. Shah S, et al. Among authors: singh g. Drug Dev Ind Pharm. 2025 Jan 15:1-14. doi: 10.1080/03639045.2025.2453533. Online ahead of print. Drug Dev Ind Pharm. 2025. PMID: 39815752
8,492 results